InvestorsHub Logo
icon url

CaptainObvious

05/24/21 7:44 AM

#380343 RE: Lykiri #380342

This guy may be a double agent.
icon url

MI Dendream

05/24/21 7:51 AM

#380348 RE: Lykiri #380342

This quite the change in course. Any idea what gives?

To me this casts doubt on the loaner program idea that I once ignored, but later reconsidered. Now, I am back to thinking that he is just like the rest of the class and is bouncing from opportunity to opportunity based on his own personal reasons. I know one of his first degree contacts. I may do some digging if I have time, but don’t really want to waste time on a rabbit hole.


icon url

spartex

05/24/21 8:25 AM

#380358 RE: Lykiri #380342

Wow, fascinating. Regeneron is working on the PD-1 inhibition area of cancer research and Bispecific antibodies.


https://www.regeneron.com/science/research-areas
icon url

tryn2

05/24/21 8:27 AM

#380359 RE: Lykiri #380342

Is Duffy going to yet another promising company to 'help them with their FDA interactions...???
icon url

Truthfan

05/24/21 8:29 AM

#380361 RE: Lykiri #380342

“New job for Kevin Duffy.”




Nuggets of information everywhere allow for speculation:

P. Roy Vagelos, MD, is currently Chairman of the Board of Regeneron and past CEO of Merck & Co.